Prevention of mother-to-child transmission of HIV in the HAART era: patterns in use of neonatal prophylaxis by unknown
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Prevention of mother-to-child transmission of HIV in the HAART 
era: patterns in use of neonatal prophylaxis
K England
Address: UCL Institute of Child Health, London, UK
Background
With increasing use of HAART in pregnancy, there are con-
cerns regarding the safety of exposure to combinations of
antiretroviral drugs in pregnancy and neonatal life. Clini-
cal trial data are unavailable regarding the efficacy of dif-
ferent neonatal prophylactic regimens for infants born to
women on HAART. There is increasing recognition of the
need to balance reducing MTCT risk and minimizing
fetal/neonatal ART exposure.
Methods
In the European Collaborative Study, HIV-infected preg-
nant women are enrolled and their infants followed in 10
European countries. Data on 2,674 mother-child pairs
enrolled in the western European sites between January
1998 and June 2008 were analysed, and patterns of neo-
natal prophylaxis, MTCT rates, and risk of infant anaemia
investigated.
Summary of results
Overall, 1,820 (68%) women received HAART in preg-
nancy, 297 (11%) zidovudine (ZDV) monotherapy and
the remainder no antenatal ART. Of the 1,820 mother-
child pairs with antenatal HAART use, the majority of
infants received neonatal prophylaxis with ZDV, although
303 (17%) received a combination of two or more drugs.
Of the 1,275 children with duration of ZDV prophylaxis
available, 185 (14%) received ZDV for 2 weeks (all intra-
venously), and the remainder received oral ZDV: 95 (7%)
for 4 weeks and 947 (74%) for 6 weeks. Among infants
born to women receiving no antenatal ART, 24 (9%)
received three drugs. There were trends in the type and
duration of neonatal prophylaxis over the 10-year period.
The proportion of children receiving 6 weeks of ZDV
decreased from 82% in 1998–2000 to 63% after 2004 (p
< 0.001) while the proportion receiving ZDV for 4 weeks
increased during the same periods from 3% to 19% (p <
0.001). Of children born to women on HAART, the pro-
portion receiving at least two drugs decreased over the 10-
year period from 23% in 1998–2000 to 16% after 2004 (p
= 0.02). With this decrease, the proportion of children
experiencing severe anaemia during the same period
halved, from 4% in 1998–2000 to 2% after 2004. The
overall MTCT rate was 2.6% (95% CI 2.0–3.4%) and 1.4%
(95% CI 0.8–2.2%) among infants of mothers receiving
HAART; in the latter group the MTCT rate was 0.9% for
those receiving ZDV monotherapy and 1.6% for those on
two or more drugs.
Conclusion
In the absence of evidence from clinical trials, practices for
prescribing neonatal prophylaxis vary in the HAART era,
with evidence of shorter durations in recent years. Preva-
lence of severe anaemia among infants exposed to ART in
utero and early life remains low overall.
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